Mahmoud Ghazzi joins Daiichi Sankyo

As executive vice president of drug development for the Americas

Mahmoud Ghazzi has joined Daiichi Sankyo Pharma Development (DSPD) as its new executive vice president of drug development for the Americas.

DSPD, headquartered in Edison, NJ, runs clinical trials throughout the region and Ghazzi will work closely with the global development regional heads in Asia, Japan and Europe to ensure delivery of clinical development programmes.

He will oversee critical regional functions such as clinical development, regulatory affairs, translational medicine and clinical pharmacology and clinical safety and pharmacovigilance. He also be co-chairman of the Daiichi Sankyo Global Clinical Committee, which ensures that all programmes meet the highest standards.

Prior to joining DSPD, Ghazzi served in roles of increasing responsibility at GlaxoSmithKline (GSK) and Pfizer where he developed and managed clinical trials for cardiovascular, metabolism, obesity and diabetes drugs.

You may also like

Regulatory

AstraZeneca & Daiichi Sankyo's Enhertu bags another approval for gastric cancer applications

The HER2-targeting ADC has received conditional approval owing to the results of the DESTINY-Gastric06 Phase II trial
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Latest EU drug approvals span range of health issues

Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Reimbursment issues hinder future development of personal therapies

The development of more targeted therapies is moving apace, but are the payers prepared for it? Dr Sarah Houlton looks at the progress of personalised medicines
Regulatory

Opioid-induced constipation – naloxegol

About half of all patients taking opioids commonly experience constipation
Regulatory

Ranbaxy takes action to redress previous conduct

Daiichi Sankyo believes former shareholders of Ranbaxy concealed information during FDA probe
Regulatory

Anticancer agent – tivantinib

The proto-oncogene c-MET plays many roles in the propagation of tumours, so blocking its activity has great potential
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Looking ahead to a challenging year

Asia is emerging as a rival to the US as a leading source of drug discovery and high end innovation. Both clinical trials activity and investments by drug majors are set to expand in Asia, with India and China leading the charge. But the Indian, Chinese and Philippino governments are proposing to increase price controls on medicines, and lax intellectual property laws across the region could hinder growth.
Subscribe now